136 related articles for article (PubMed ID: 37793170)
1. Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity.
Falade-Nwulia O; Lesko CR; Fojo AT; Keruly JC; Moore RD; Sutcliffe CG; Mehta SH; Chander G; Thomas DL; Sulkowski M
J Infect Dis; 2024 Mar; 229(3):775-779. PubMed ID: 37793170
[TBL] [Abstract][Full Text] [Related]
2. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands.
Isfordink CJ; Smit C; Boyd A; de Regt MJA; Rijnders BJA; van Crevel R; Ackens RP; Reiss P; Arends JE; van der Valk M;
AIDS; 2022 May; 36(6):773-783. PubMed ID: 34999607
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C microelimination among people living with HIV in Taiwan.
Chen GJ; Ho SY; Su LH; Chang SY; Hsieh SM; Sheng WH; Liu WD; Huang YS; Lin KY; Chen YT; Su YC; Liu WC; Sun HY; Hung CC
Emerg Microbes Infect; 2022 Dec; 11(1):1664-1671. PubMed ID: 35608049
[TBL] [Abstract][Full Text] [Related]
4. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
5. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
6. Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIV.
Requena MB; Grabar S; Lanoy E; Pialoux G; Billaud E; Duvivier C; Merle P; Piroth L; Tattevin P; Salmon D; Weiss L; Costagliola D; Lacombe K
AIDS; 2023 Jul; 37(8):1297-1306. PubMed ID: 37070541
[TBL] [Abstract][Full Text] [Related]
7. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
[TBL] [Abstract][Full Text] [Related]
8. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
9. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
10. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
11. Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
Hlavay BA; Zhuo R; Ogando N; Charlton C; Stapleton JT; Klein MB; Power C
J Clin Virol; 2023 May; 162():105445. PubMed ID: 37043902
[TBL] [Abstract][Full Text] [Related]
12. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
[TBL] [Abstract][Full Text] [Related]
13. The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
Chromy D; Bauer DJM; Simbrunner B; Jachs M; Hartl L; Schwabl P; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Mandorfer M; Gschwantler M; Reiberger T
J Viral Hepat; 2022 May; 29(5):385-394. PubMed ID: 35274399
[TBL] [Abstract][Full Text] [Related]
14. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
15. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
16. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
17. Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
Garvey LJ; Cooke GS; Smith C; Stingone C; Ghosh I; Dakshina S; Jain L; Waters LJ; Mahungu T; Ferro F; Sood C; Freeman C; Phillips C; Dhairyawan R; Burholt R; Sharp H; Ullah S; Gilleece Y; Brown A; Orkin C; Rodger A; Bhagani S
Clin Infect Dis; 2021 Jan; 72(2):233-238. PubMed ID: 32211763
[TBL] [Abstract][Full Text] [Related]
18. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
19. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment.
Brothers S; DiDomizio E; Nichols L; Brooks R; Villanueva M
AIDS Behav; 2023 Jan; 27(1):119-133. PubMed ID: 35776253
[TBL] [Abstract][Full Text] [Related]
20. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
